Share
11,137 Posts.
lightbulb Created with Sketch. 3791
clock Created with Sketch. 19/12/22
10:07
Share
Originally posted by Spectreau:
↑
Macquarie has just updated CXO back to outperform. Maintains $1.30 PT but lists upcoming catalysts as "Completion of the first DSO shipment and confirmation of progress of the spodumene concentrate plant construction present key near-term catalysts for CXO. " Macquarie recommendations Upgrading from Neutral to Outperform: We believe the regional explorationpotential of the Finniss project is strong and will become more recognised once spodumene production commences in 2023. Our development scenario for Finniss is based on a mining inventory equivalent to two thirds of current resources. Upgrades to the resource base are likely in our view to capture the recent drilling results. CXO’s share price is down 43% over the past month, significantly outpacing the 9% fall in spot China lithium carbonate prices over the same period (ASX200 <1% move). We expect CXO to generate strong cash flow once spodumene production commences, with the stock trading on FY24 and FY25 free cash flow yields of 14% and 37%, respectively "
Expand
Beautiful .... didn't they just short CXO and others. Is there further depth to their commentary regarding pricing of SC once we get past the DSO $$.FY24 and FY25 free cash flow yields of 14% and 37%, respectively"
